共 50 条
Korean Medication Algorithm for Depressive Disorder: Comparisons with Other Treatment Guidelines
被引:17
|作者:
Wang, Hee Ryung
[1
]
Bahk, Won-Myong
[1
]
Seo, Jeang Seok
[2
]
Woo, Young Sup
[1
]
Park, Young -Min
[3
]
Jeong, Jong-Hyun
[4
]
Kim, Won
[5
,6
]
Shim, Se-Hoon
[7
]
Lee, Jung Goo
[8
,9
,10
]
Jon, Duk-In
[11
]
Min, Kyung Joon
[12
]
机构:
[1] Catholic Univ Korea, Dept Psychiat, Coll Med, Seoul, South Korea
[2] Konkuk Univ, Dept Psychiat, Sch Med, Chungju, South Korea
[3] Inje Univ, Coll Med, Dept Psychiat, Ilsan Paik Hosp, Goyang, South Korea
[4] Catholic Univ Korea, St Vincents Hosp, Dept Psychiat, Coll Med, Suwon, South Korea
[5] Inje Univ, Sch Med, Dept Psychiat, Seoul Paik Hosp, Seoul, South Korea
[6] Inje Univ, Stress Res Inst, Seoul, South Korea
[7] Soonchunhyang Univ, Dept Psychiat, Coll Med, Cheonan Hosp, Cheonan, South Korea
[8] Inje Univ, Dept Psychiat, Coll Med, Haeundae Paik Hosp, Busan, South Korea
[9] Inje Univ, Palk Inst Clin Res, Busan, South Korea
[10] Inje Univ, Dept Hlth Sci & Technol, Grad Sch, Busan, South Korea
[11] Hallym Univ, Sacred Heart Hosp, Dept Psychiat, Coll Med, Anyang, South Korea
[12] Chung Ang Univ, Dept Psychiat, Coll Med, Seoul, South Korea
关键词:
Depressive disorder;
Expert consensus;
Guideline;
KMAP DD 2017;
Therapy;
PSYCHIATRY WFSBP GUIDELINES;
2016 CLINICAL GUIDELINES;
BIOLOGICAL TREATMENT;
CANADIAN NETWORK;
WORLD FEDERATION;
MOOD;
MANAGEMENT;
SOCIETIES;
ADULTS;
LEVOMILNACIPRAN;
D O I:
10.9758/cpn.2017.15.3.199
中图分类号:
Q189 [神经科学];
学科分类号:
071006 ;
摘要:
In this review, we compared recommendations from the Korean Medication Algorithm Project for Depressive Disorder 2017 (KMAP DD 2017) to other global treatment guidelines for depression. Six global treatment guidelines were reviewed; among the six, 4 were evidence based guidelines, 1 was an expert consensus based guideline, and 1 was an amalgamation of both evidence and expert consensus based recommendations. The recommendations in the KMAP DD 2017 were generally similar to those in other global treatment guidelines, although there were some differences between the guidelines. The KMAP DD 2017 appeared to reflect current changes in the psychopharmacology of depression quite well, like other recently published evidence based guidelines. As an expert consensus based guideline, the KMAP DD 2017 had some limitations. However, considering there are situations in which clinical evidence cannot be drawn from planned clinical trials, the KMAP DD 2017 may be,helpful for Korean psychiatrists making decisions in the clinical settings by complementing previously published evidence based guidelines.
引用
收藏
页码:199 / 209
页数:11
相关论文